Analysts Offer Predictions for Zimmer Biomet Q3 Earnings

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) – Equities research analysts at Zacks Research decreased their Q3 2025 earnings estimates for Zimmer Biomet in a research note issued on Monday, March 10th. Zacks Research analyst R. Department now forecasts that the medical equipment provider will post earnings per share of $1.93 for the quarter, down from their previous estimate of $1.96. The consensus estimate for Zimmer Biomet’s current full-year earnings is $8.22 per share. Zacks Research also issued estimates for Zimmer Biomet’s Q4 2025 earnings at $2.49 EPS.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 EPS for the quarter, topping the consensus estimate of $2.30 by $0.01. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. During the same quarter in the prior year, the firm earned $2.20 EPS.

Other research analysts also recently issued reports about the stock. Royal Bank of Canada reduced their price objective on shares of Zimmer Biomet from $130.00 to $125.00 and set an “outperform” rating on the stock in a research report on Friday, February 7th. Raymond James dropped their price objective on shares of Zimmer Biomet from $126.00 to $119.00 and set an “outperform” rating on the stock in a research note on Friday, February 7th. Stifel Nicolaus boosted their price objective on shares of Zimmer Biomet from $130.00 to $138.00 and gave the stock a “buy” rating in a research note on Thursday, January 23rd. Barclays dropped their price objective on shares of Zimmer Biomet from $118.00 to $112.00 and set an “underweight” rating on the stock in a research note on Monday, February 10th. Finally, JMP Securities reaffirmed a “market outperform” rating and issued a $140.00 target price on shares of Zimmer Biomet in a report on Friday, February 7th. Two analysts have rated the stock with a sell rating, eleven have issued a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat, Zimmer Biomet presently has an average rating of “Hold” and an average price target of $124.15.

Zimmer Biomet Stock Down 3.0 %

Shares of NYSE ZBH opened at $107.36 on Wednesday. The company has a quick ratio of 0.99, a current ratio of 1.91 and a debt-to-equity ratio of 0.43. Zimmer Biomet has a 52 week low of $97.69 and a 52 week high of $133.90. The firm’s fifty day moving average is $105.68 and its 200 day moving average is $107.08. The company has a market cap of $21.37 billion, a price-to-earnings ratio of 24.13, a PEG ratio of 1.95 and a beta of 1.04.

Institutional Investors Weigh In On Zimmer Biomet

Hedge funds have recently bought and sold shares of the business. Roman Butler Fullerton & Co. purchased a new stake in shares of Zimmer Biomet in the fourth quarter valued at $473,000. Geode Capital Management LLC increased its stake in Zimmer Biomet by 2.6% in the 3rd quarter. Geode Capital Management LLC now owns 4,879,385 shares of the medical equipment provider’s stock worth $524,942,000 after buying an additional 125,852 shares during the period. M&T Bank Corp increased its stake in Zimmer Biomet by 48.4% in the 3rd quarter. M&T Bank Corp now owns 26,719 shares of the medical equipment provider’s stock worth $2,884,000 after buying an additional 8,709 shares during the period. KLCM Advisors Inc. purchased a new position in Zimmer Biomet in the 4th quarter worth about $7,825,000. Finally, Peddock Capital Advisors LLC purchased a new position in Zimmer Biomet in the 4th quarter worth about $654,000. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Insiders Place Their Bets

In related news, SVP Lori Winkler sold 1,443 shares of the company’s stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $104.40, for a total transaction of $150,649.20. Following the completion of the transaction, the senior vice president now owns 8,768 shares in the company, valued at approximately $915,379.20. This represents a 14.13 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 0.95% of the company’s stock.

Zimmer Biomet Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be given a $0.24 dividend. The ex-dividend date is Monday, March 31st. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.89%. Zimmer Biomet’s payout ratio is currently 21.57%.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.